Literature DB >> 25131931

MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.

Jianwei Li1, Feng Tian1, Dajiang Li1, Jian Chen1, Peng Jiang1, Shuguo Zheng1, Xiaowu Li1, Shuguang Wang2.   

Abstract

The aberrant expression of PSMD10 has important functions in various malignancies. This study showed that PSMD10 was highly expressed and inversely correlated with the expression of miR-605 in intrahepatic cholangiocarcinoma (ICC) specimens. MiR-605 directly targeted and repressed PSMD10 expression. In addition, over-expression of miR-605 inhibited ICC cell progression both in vitro and in vivo. This effect of miR-605 on ICC cells was similar to that of PSMD10 knock-down by RNAi. Moreover, restoration of PSMD10 could reverse the phenotypic alteration caused by miR-605 in ICC cells. These results suggest a new therapeutic strategy in ICC by restoring miR-605, which is regulated by p53.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Intrahepatic cholangiocarcinoma; Invasion; Proteasome 26S subunit non-ATPase 10; miR-605

Mesh:

Substances:

Year:  2014        PMID: 25131931     DOI: 10.1016/j.febslet.2014.08.008

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

Review 1.  The role of miRNAs in cholangiocarcinoma.

Authors:  Jessica A Howell; Shahid A Khan
Journal:  Hepat Oncol       Date:  2016-03-29

Review 2.  Gankyrin as a potential target for tumor therapy: evidence and perspectives.

Authors:  Haixai Li; Junyan Zhang; Cheng Zhen; Baojun Yang; Limin Feng
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

3.  LncRNA PCAT6 increased cholangiocarcinoma cell proliferation and invasion via modulating miR-330-5p.

Authors:  Yongjie Xin; Xu He; Wei Zhao; Meixiao Zhan; Yong Li; Jing Xiao; Ke He; Ligong Lu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 4.  Gankyrin as a potential therapeutic target for cancer.

Authors:  Chongchong Wang; Li Cheng
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

5.  miR-188-5p and Host MALAT1 Regulate RBE Cell Migration, Invasion, and Apoptosis via Up-regulating PSMD10 in Cholangiocarcinoma.

Authors:  Zhaoqiang Yin; Jianlong Wang; Tao Li; Lifeng Ma; Jiansheng Kang; Guochao Liu
Journal:  Appl Biochem Biotechnol       Date:  2022-09-19       Impact factor: 3.094

Review 6.  Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview.

Authors:  Simone Brivio; Massimiliano Cadamuro; Luca Fabris; Mario Strazzabosco
Journal:  Gene Expr       Date:  2017-10-25

Review 7.  Gankyrin regulates cell signaling network.

Authors:  Xinxin Wang; Bin Jiang; Yanjie Zhang
Journal:  Tumour Biol       Date:  2016-01-27

8.  Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.

Authors:  Anthony Wood; Saby George; Nabil Adra; Sreenivasulu Chintala; Nur Damayanti; Roberto Pili
Journal:  Invest New Drugs       Date:  2019-10-25       Impact factor: 3.850

Review 9.  Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Authors:  Antonio Cigliano; Xin Chen; Diego F Calvisi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-04-23       Impact factor: 3.869

Review 10.  The role of microRNAs in intrahepatic cholangiocarcinoma.

Authors:  Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  J Cell Mol Med       Date:  2016-09-13       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.